Effects of Blood Pressure Lowering in Patients with Acute Ischemic Stroke and Carotid Artery Stenosis

Abstract

Background

The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke. In the present analysis we wanted to see if the effects of blood pressure lowering are harmful in the subgroup of patients with carotid artery stenosis.

Methods

SCAST was a randomized- and placebo-controlled, double-masked trial of 2029 patients with acute stroke and high systolic blood pressure (≥140 mmHg). Of 1733 patients with ischemic stroke 993 underwent carotid artery imaging, and the degree of stenosis was categorized as no/insignificant (0–49%, n = 806), moderate (50–69%, n = 97) or severe (=70%, n = 90). The trial's two co-primary effect variables were the composite end-point of vascular death, stroke or myocardial infarction, and functional outcome at six-months, according to the modified Rankin Scale.

Results

Among patients with moderate or severe carotid artery stenosis the vascular end-point occurred in 9 of 87 patients (10·3%) treated with candesartan and in 17 of 100 controls (17·0%), and there was no evidence of a different risk in patients with severe stenosis (adjusted hazard ratio 0·74, 95% confidence interval 0·28–1·96, P = 0·54). For functional outcome there was also no clear difference, although in patients with severe stenosis the risk of a poor outcome was somewhat higher than in any of the other groups (adjusted odds ratio 2·24, 95% confidence interval 0·71–7·09, P = 0·16). Progressive stroke also occurred more often in patients with carotid artery stenosis treated with candesartan (10 of 87 patients (11·5%) vs. 4 of 100 patients (4·0%)), with a trend towards an increased risk with increasing severity of stenosis (P-value for linear trend = 0·04).

Conclusions

There is no clear evidence that the effect of candesartan is qualitatively different in patients with carotid artery stenosis, but there are signals that patients with severe stenosis are at particularly high risk of stroke progression and poor functional outcome.

Keywords

acute stroke blood pressure candesartan carotid stenosis cerebral autoregulation

Get full access to this article

View all access options for this article.

References

Wolff

Guirguis-Blake

Miller

Gillespie

Harris

. Screening for carotid artery stenosis: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 147:860–70.

Spence

. Management of resistant hypertension in patients with carotid stenosis: high prevalence of renovascular hypertension. Cerebrovasc Dis 2000; 10:249–54.

Leonardi-Bee

Bath

Phillips

Sandercock

, IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315–20.

Sprigg

Gray

Bath

. Relationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: data from the TAIST trial. J Hypertens 2006; 24:1413–7.

Qureshi

Ezzeddine

Nasar

. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007; 25:32–8.

Van der Grond

Balm

Kappelle

. Cerebral metabolism of patients with stenosis or occlusion of the internal carotid artery. A 1H-MR spectroscopic imaging study. Stroke 1995; 26:822–8.

Vernieri

Pasqualetti

Passarelli

Rossini

Silvestrini

. Outcome of carotid artery occlusion is predicted by cerebrovascular reactivity. Stroke 1999; 30:593–8.

Powers

. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991; 29:231–40.

Grubb

Jr Derdeyn

Fritsch

. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 1998; 280:1055–60.

10.

Rothwell

Howard

Spence

. Carotid Endarterectomy Trialists' Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 2003; 34:2583–90.

11.

Sandset

Bath

Boysen

. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741–50.

12.

Sandset

Murray

Boysen

. Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). Int J Stroke 2010; 5:423–7.

13.

European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 1991; 337:1235–43.

14.

North American Symptomatic Carotid Endarterectomy Trial Steering Committee. North American symptomatic carotid endarterectomy trial. Methods, patient characteristics, and progress. Stroke 1991; 22:711–20.

15.

Jauch

Saver

Adams

. American heart association stroke council; council on cardiovascular nursing; council on peripheral vascular disease; council on clinical cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870–947.

16.

European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457–507.

17.

Sare

Gray

Wardlaw

Chen

Bath

. Is lowering blood pressure hazardous in patients with significant ipsilateral carotid stenosis and acute ischaemic stroke? Interim assessment in the ‘Efficacy of Nitric Oxide in Stroke’ trial. Blood Press Monit 2009; 14:20–5.

18.

Paciaroni

Agnelli

Caso

. Effect of carotid stenosis on the prognostic value of admission blood pressure in patients with acute ischemic stroke. Atherosclerosis 2009; 206:469–73.

19.

Stead

Gilmore

Decker

Weaver

Brown

Jr . Initial emergency department blood pressure as predictor of survival after acute ischemic stroke. Neurology 2005; 65:1179–83.

20.

Vemmos

Tsivgoulis

Spengos

. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004; 255:257–65.

21.

Britton

De Faire

Helmers

. Hazards of therapy for excessive hypertension in acute stroke. Acta Med Scand 1980; 207:253–7.

22.

Ruff

Talman

Petito

. Transient ischemic attacks associated with hypotension in hypertensive patients with carotid artery stenosis. Stroke 1981; 12:353–5.

23.

Nishimura

Ito

Saavedra

. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31:2478–86.

24.

Fornes

Richer

Vacher

Bruneval

Giudicelli

. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22:305–13.

25.

Inada

Wada

Ojima

. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1079–99.

26.

Wada

Kanagawa

Ishimura

Inada

Nishikawa

. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 1995; 13:113–22.

27.

Walters

Bolster

Dyker

Lees

. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 2001; 32:473–8.

28.

Schrader

Luders

Kulschewski

. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699–703.

29.

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033–41.

30.

Schrader

Luders

Kulschewski

. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218–26.

31.

Yusuf

Diener

Sacco

. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225–37.

32.

The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 2006; 1:245–9.